13F Filings/TYBOURNE CAPITAL MANAGEMENT HK LTD

TYBOURNE CAPITAL MANAGEMENT HK LTD

Hedge FundCIK0001553936LocationHONG KONG, Hong Kong XXXXX, United States

Long U.S. equity positions disclosed to the SEC on Form 13F-HR.

Latest filingQ3 2025Quarter ended30 Sept 2025Filed6 Nov 2025
Firm profile · Form ADV
SEC adviser registration
CRD
164723 · 802-76945
Portfolio Turnover
18%
Of book traded, QoQ
Positions
4
Long U.S. equities
Top 10 Concentration
100%
Of reported value
QoQ Change
$-3.6M
Value change
Assets under management
Form ADV RAUM · client mix · 13F over time
13F AUM over time
$31M
Q3 ’25 · 13F AUM
95%
50 quarters
Reported Holdings
Q3 2025 · upgrade to Pro for past quarters
★ Position spotlightTSHATAYSHA GENE THERAPIES INC (TSHA US) · 39.1% of bookThis highlighted stock and its 1Y chart are public
Loading position history…
SecuritySharesMarket ValueEst. CostLast PxEst. Return% PortfolioΔ SharesAction
TAYSHA GENE THERAPIES INC (TSHA US)
TSHA· Health Care
3.70MSH$12.1M~$3.27$5.9782.6%39.1% 9.6%Reduced
FORTE BIOSCIENCES INC (FBRX US)
FBRX· Health Care
787KSH$11.8M~$15.00$76.95413.0%38.1%Unchanged
ALUMIS INC (ALMS US)
ALMS· Health Care
1.40MSH$5.6M~$3.99$23.03477.2%18.0%Unchanged
ZENTALIS PHARMACEUTICALS INC (ZNTL US)
ZNTL· Health Care
961KSH$1.5M~$1.51$3.76149.0%4.7% 35.0%Reduced
TSHATAYSHA GENE THERAPIES INC (TSHA US)Reduced
$12.1M· 39.1%· 3.70M SH· 9.6%· cost $3.27· last $5.97· 82.6%
Health Care · COM SHS · SOLE
FBRXFORTE BIOSCIENCES INC (FBRX US)Unchanged
$11.8M· 38.1%· 787K SH· · cost $15.00· last $76.95· 413.0%
Health Care · COM NEW · SOLE
ALMSALUMIS INC (ALMS US)Unchanged
$5.6M· 18.0%· 1.40M SH· · cost $3.99· last $23.03· 477.2%
Health Care · COM · SOLE
ZNTLZENTALIS PHARMACEUTICALS INC (ZNTL US)Reduced
$1.5M· 4.7%· 961K SH· 35.0%· cost $1.51· last $3.76· 149.0%
Health Care · COM · SOLE
Sector Breakdown
Q3 2025
Health Care100.0% · $30.9M